Psychotropic medications and the treatment of human prion diseases.
Prion diseases are rare, rapidly progressive, fatal neurodegenerative illnesses caused by an abnormal isoform of the native prion protein. Creutzfeldt-Jakob disease (CJD) is the most prevalent human prion disease with three possible etiologies: sporadic, genetic, and acquired. Although acquired forms of prion disease have received the most attention, most cases are sporadic or genetic and are thus unpreventable. There is some literature on neurotransmitter system dysregulation in animal and human models of prion diseases. Several studies indicate that there is a disproportional amount of serotonin dysregulation in prion diseases and that prion-mediated cytotoxicity may be blocked by N-methyl D-aspartate (NMDA) receptor antagonists. Prion disease therapeutic investigations have mainly consisted of basic science research, which has elucidated the importance of molecular structure in preventing prion protein conversion. Typical neuroleptics and tricyclic antidepressants have been the primary psychotropic medications studied in humans due to their heterocyclic structures. Recent studies have correlated lipid disruption to these structurally similar compounds with antiprion activity. Preliminary studies suggest that lithium mediated inhibition of glycogen synthetase kinase 3 and lithium-induced autophagy may be avenues for further research. Many studies require replication in other experimental settings. Thus far, treatment strategies have focused on aborting prion protein conversion and as such have limited therapeutic usefulness given the rapidity of disease progression and difficulty in establishing ante-mortem diagnoses of prion diseases. There is a paucity of research examining the prevention of prion diseases in at risk populations (i.e. genetic and acquired prion diseases).
Appleby
Brian S
BS
Johns Hopkins University School of Medicine, Department of Psychiatry and Behavioral Sciences, Division of Geriatric Psychiatry and Neuropsychiatry, Baltimore, MD, USA. bappleb1@jhmi.edu
D000927:Anticonvulsants / Q000627:therapeutic use; D000928:Antidepressive Agents / Q000627:therapeutic use*; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D006801:Humans; D008094:Lithium / Q000627:therapeutic use; D009474:Neurons / Q000187:drug effects / Q000378:metabolism; D018377:Neurotransmitter Agents / Q000378:metabolism; D017096:Prion Diseases / Q000188:drug therapy*
D000927:Anticonvulsants; D000928:Antidepressive Agents; D014150:Antipsychotic Agents; D018377:Neurotransmitter Agents; D008094:Lithium